Edgewise Therapeutics, Inc. (EWTX)
| Market Cap | 3.68B +140.1% |
| Revenue (ttm) | n/a |
| Net Income | -176.01M |
| EPS | -1.66 |
| Shares Out | 107.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,167,042 |
| Open | 33.18 |
| Previous Close | 33.30 |
| Day's Range | 33.12 - 34.58 |
| 52-Week Range | 12.15 - 39.96 |
| Beta | 0.25 |
| Analysts | Buy |
| Price Target | 43.67 (+27.84%) |
| Earnings Date | May 7, 2026 |
About EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical tr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for EWTX stock is "Buy." The 12-month stock price target is $43.67, which is an increase of 27.84% from the latest price.
News
Edgewise Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
EDG-7500 offers a differentiated mechanism with robust efficacy and safety in HCM, avoiding ejection fraction reduction and enabling easier real-world use. Upcoming data and regulatory feedback may further support its broad adoption, while the Grand Canyon study aims to confirm functional benefits in dystrophies.
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026
BOULDER, Colo., May 12, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present at th...
Edgewise Therapeutics Quarterly report: Q1 2026
Edgewise Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Edgewise Therapeutics Earnings release: Q1 2026
Edgewise Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Edgewise Therapeutics reports Q1 EPS (46c), consensus (49c)
Cash, cash equivalents and marketable securities were approximately $499.6M as of March 31.”For the first time with an investigational agent, we have generated long-term data showing that people with ...
Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications
– Announced positive long-term sevasemten data demonstrating sustained functional stabilization in Becker muscular dystrophy (Becker) up to 3.5 years of follow-up – – CIRRUS-HCM 12-week data of EDG-...
Edgewise Therapeutics price target raised to $52 from $46 at Truist
Truist raised the firm’s price target on Edgewise Therapeutics (EWTX) to $52 from $46 and keeps a Buy rating on the shares. The firm is citing the company’s ACACIA data…
Edgewise Therapeutics rises 18.1%
Edgewise Therapeutics (EWTX) is up 18.1%, or $5.70 to $37.15.
Cytokinetics Phase 3 data bodes well for Edgewise, says Raymond James
Cytokinetics (CYTK) reported statistically positive Phase 3 ACACIA results for aficamten in non-obstructive hypertrophic cardiomyopathy, an outcome that bodes well for Edgewise Therapeutics (EWTX), as...
Edgewise Therapeutics rises 23.3%
Edgewise Therapeutics (EWTX) is up 23.3%, or $7.33 to $38.78.
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., May 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics ...
Edgewise Therapeutics Proxy statement: Proxy filing
Edgewise Therapeutics filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Edgewise Therapeutics Proxy statement: Proxy filing
Edgewise Therapeutics filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
JPMorgan ups Edgewise target, adds to Analyst Focus List
JPMorgan raised the firm’s price target on Edgewise Therapeutics (EWTX) to $45 from $34 and keeps an Overweight rating on the shares. JPMorgan also added Edgewise to its Analyst Focus…
Edgewise Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Key cardiovascular and neuromuscular programs are advancing, with 7500 showing a favorable safety profile and plans for Phase III in HCM by year-end. Becker muscular dystrophy data indicate disease stabilization, and new HFpEF candidates are progressing.
Edgewise Therapeutics’ sevasemten shows efficacy in Becker disorder
Edgewise Therapeutics (EWTX) presented long-term data from its MESA open-label extension study of sevasemten in Becker muscular dystrophy, a genetic disorder with no approved therapeutic interventions...
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up
–The MESA data show stabilization of function in participants on sevasemten versus the predicted functional decline observed in Becker natural history studies – – Data reinforce prior clinical finding...
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026
BOULDER, Colo., March 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present at t...
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference
BOULDER, Colo., March 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 2026 Muscular Dys...
Edgewise Therapeutics price target raised to $45 from $30 at Evercore ISI
Evercore ISI raised the firm’s price target on Edgewise Therapeutics (EWTX) to $45 from $30 and keeps an Outperform rating on the shares.
Edgewise Therapeutics reports Q4 EPS (47c), consensus (44c)
Cash, cash equivalents and marketable securities were approximately $530.1M as of December 31, 2025. “Following strong execution in 2025, we have entered a transformative year,” said CEO Kevin Koch. “...
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs
– CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026 – – Phase 1 healthy adult trial data of EDG-15400 and plans for heart f...
Edgewise Therapeutics Annual report: Q4 2025
Edgewise Therapeutics has published its Q4 2025 annual report on February 26, 2026.
Edgewise Therapeutics Earnings release: Q4 2025
Edgewise Therapeutics released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
Edgewise Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Major milestones include an upcoming phase III readout for sevasemten in Becker, CIRRUS Part D data in HCM, and phase I initiation for EDG-15400. Enhanced trial designs and strong patient retention support commercial prospects, with phase III HCM trials set for Q4.